Skip to main content

Press releases | October 3, 2022

Fried Frank acted as counsel to AmplifyBio in its acquisition of select assets from PACT Pharma, Inc. (“PACT”). AmplifyBio is a contract research organization (CRO) focused on accelerating innovation across pharmaceutical modalities. PACT is a privately held biopharmaceutical company developing neoantigen-specific T cell receptor cell therapies. With the acquisition of these assets, AmplifyBio aims to provide an early, consistent characterization of a treatment's purity, potency, and viability throughout the life cycle of therapeutic development.

The Fried Frank team was led by corporate partner Andrea Gede-Lange and intellectual property and technology partner Amir Ghavi and included litigation partner Michael Keats, restructuring and insolvency partner Adam L. Shiff, tax partner Shane Hoffman, corporate real estate special counsel Jessica Mayes, and corporate associates Nathan Jablow and Karis Stubblefield.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.